Osteosarcoma Recurrent clinical trials at UCSF

• Olaparib With Ceralasertib in Recurrent Osteosarcoma

  open to eligible people ages 12-30

  This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: - Olaparib - Ceralasertib

  San Francisco, California and other locations

Last updated: October 12, 2021